

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT: Haines, et al.  
SERIAL NUMBER: 10/540,635 EXAMINER : Sean M. Basquill  
FILING DATE: December 12, 2005 ART UNIT : 1612  
FOR: ANTI-INFLAMMATORY FORMULATIONS

**VIA EFS**

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed after the mailing date of the Final Action, but before the mailing date of Notice of Allowance under 37 C.F.R. §1.311. The fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed. This Supplemental Information Disclosure Statement is being filed within three months of the mailing date of the Supplementary Partial European Search Report in the corresponding EP application No. 04 75 7067, mailed April 28, 2009.

References A6-A7 and B4-B6 contained in this Supplemental Information Disclosure Statement were first cited in a Supplementary Partial European Search Report in a counterpart application, which was communicated to Applicants' U.S. attorneys on April 28, 2009. This communication was not received by any individual designated in 1.56(c) more than thirty days prior to the filing of the information disclosure statement.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make

APPLICANT: Haines, et al.  
U.S.S.N.: 10/540,635

no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 21534-002 CIP NATL.

Respectfully submitted,

Ingrid A. Beattie

Ingrid A. Beattie, Reg. No. 42,306  
Attorney(s) for Applicants  
c/o MINTZ, LEVIN  
Address all written correspondence to  
**Customer no.: 30623**  
Tel: (617) 542-6000  
Fax: (617) 542-2241

4612686v.1